Relay Therapeutics Upsizes ATM to $463M, Reports $911M Cash and Pipeline Progress
RLAY has more than doubled off its 52-week low of $3.025.
Summary
Relay Therapeutics increased its ATM program to $463 million, with $213 million in new shares available for sale, while reporting $911 million in cash and advancing its zovegalisib program in breast cancer and vascular anomalies.
Key Events · Financing and Capital Events · RLAY
-
ATM Program Upsized to $463M
Amendment increases total ATM capacity from $250M to $462.98M, with $212.98M in new shares available for sale through TD Cowen; $162.98M already sold under prior agreement.
-
Q2 2026 Cash Position at $910.9M
Cash, equivalents, and investments rose to $910.9M from $642.1M in Q1, primarily due to $316M follow-on offering in May 2026; runway extends into 2029.
-
Zovegalisib Triplet Selected for 1L Breast Cancer
Zovegalisib plus atirmociclib chosen as go-forward regimen; Phase 3 trial in endocrine-sensitive patients expected to start in early 2027, subject to regulatory feedback.
-
Vascular Anomalies Data Presented
Initial Phase 1/2 data showed 60% volumetric response rate at 12 weeks; expansion cohorts opened for adults/adolescents, dose escalation ongoing for pediatric patients.
Analysis · RLAY · Life Sciences
Relay Therapeutics amended its at-the-market sales agreement with TD Cowen, increasing the total program size from $250 million to approximately $463 million. The company has already sold about $163 million under the original agreement, leaving up to $213 million in additional shares available for sale. This upsizing provides significant financial flexibility but introduces potential dilution for existing shareholders. Separately, the company reported Q2 2026 financial results: $910.9 million in cash, cash equivalents, and investments, extending its runway into 2029. The quarter saw a net loss of $83.7 million, with R&D expenses rising to $76.5 million, driven by clinical trial costs. Pipeline updates include the selection of zovegalisib plus atirmociclib as the go-forward triplet regimen for frontline breast cancer, with a Phase 3 trial expected in early 2027, and positive initial data in vascular anomalies. The strong cash position, bolstered by a $316 million follow-on offering in May 2026, supports these development plans, but the ATM amendment signals ongoing capital needs.
At the time of this filing, RLAY was trading at $19.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $3.03 to $20.79. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.